46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
Showing 1 to 8 of 8 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04608344 (ClinicalTrials.gov) | November 4, 2020 | 23/10/2020 | Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Inter ... | A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and ... | Rheumatoid Arthritis | Drug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: Filgotinib | Gilead Sciences | Galapagos NV | Completed | 18 Years | 55 Years | All | 27 | Phase 1 | United States |
| 2 | NCT04056039 (ClinicalTrials.gov) | August 14, 2018 | 21/6/2019 | Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis. Atorvastatinvs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid ... | Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity. Efficacy of Atorvastatinvs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker o ... | Cardiovascular Diseases;Arthritis, Rheumatoid | Drug: Atorvastatin;Drug: Colchicine | Hospital Central Dr. Ignacio Morones Prieto | NULL | Completed | 18 Years | N/A | All | 60 | Phase 2 | Mexico |
| 3 | ChiCTR-INR-17011772 | 2017-06-27 | 2017-06-28 | Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorva ... | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents The efficacy and safety of metformin hydrochloride combined with atorvastatinin the treatment of rhe ... | Rheumatoid Arthritis | test group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group; test group:Metformintablets, 0.25g, 3 / day, oral, atorvastatintablets 10mg, 1 / night, oral;;Contro ... | Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital ... | NULL | Recruiting | 18 | 65 | Both | test group:80;Control group:40; | China | |
| 4 | EUCTR2013-005524-42-NL (EUCTR) | 10/03/2015 | 27/03/2014 | STAtins to Prevent Rheumatoid Arthritis (STAPRA) | Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial - STAtins to Prevent Rheumatoid Arthritis (STAPRA) Prevention of rheumatoid arthritis by atorvastatinin seropositive arthralgia patients: a multi-cente ... | Rheumatoid arthritis MedDRA version: 19.0;Level: PT;Classification code 10039080;Term: Rheumatoid factor positive;System Organ Class: 10022891 - Investigations;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Rheumatoid arthritis MedDRA version: 19.0;Level: PT;Classification code 10039080;Term: Rheumatoid fa ... | Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: C10AA05 INN or Proposed INN: ATORVASTATIN Trade Name: Atorvastatin Product Name: Atorvastatin Product Code: C10AA05 INN or Proposed INN: ATORVAST ... | Reade | NULL | Not Recruiting | Female: yes Male: yes | 220 | Phase 4 | Netherlands | ||
| 5 | NCT02219191 (ClinicalTrials.gov) | August 2014 | 16/7/2014 | Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases Puerarin Versus Atorvastatinin Treating Metabolism Syndrome in Patients With Chronic Rheumatic Disea ... | The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Di ... | Rheumatoid Arthritis | Drug: puerarin tablet 50 mg;Drug: Atorvastatin tablet 20 mg | Chengdu PLA General Hospital | NULL | Active, not recruiting | 18 Years | 75 Years | All | 150 | N/A | China |
| 6 | NCT01059864 (ClinicalTrials.gov) | February 2010 | 28/1/2010 | Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 Study Of The Effects Of AtorvastatinOn Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP ... | Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind AtorvastatinOn Lipids In Pati ... | Rheumatoid Arthritis | Drug: CP-690,550;Drug: Atorvastatin;Drug: Atorvastatin Placebo | Pfizer | NULL | Completed | 18 Years | N/A | All | 111 | Phase 2 | United States;Korea, Republic of |
| 7 | EUCTR2006-006032-22-GB (EUCTR) | 04/04/2007 | 26/02/2007 | TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RA TRial of Atorvastatinfor the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - T ... | TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RA TRial of Atorvastatinfor the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - T ... | Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their cholesterol-lowering properties, but possibly through anti-inflammatory and immunomodulatory effects. This trial will assess the hypothesis that atorvastatin is more effective than placebo in the primary prevention of cardiovascular events in patients with RA. Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Stati ... | Product Name: Atorvastatin INN or Proposed INN: ATORVASTATIN | University of Manchester | Dudley Group of Hospitals NHS Trust | Not Recruiting | Female: yes Male: yes | 5350 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | United Kingdom | ||
| 8 | NCT00356473 (ClinicalTrials.gov) | March 2003 | 25/7/2006 | Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis Effects of Atorvastatinon Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid ... | Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis Effects of Atorvastatinon Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patie ... | Rheumatoid Arthritis | Drug: Atorvastatin | University of California, Los Angeles | NULL | Completed | 18 Years | N/A | Both | 20 | Phase 4 | NULL |